Last wee Ben Graham and I released a paper examining R&D spending by large pharmaceutical manufacturers. We show that the evidence does not support the idea that R&D effort has declined as a result of the Inflation Reduction Act. In fact the evidence suggests that if anything, it has increased.
Thanks Ezra its a small effort on a huge problem
Christen Linke Young, Rachel Sachs and I just put out a paper reviewing issues related to adopting International Reference Prices for prescription drugs. The link is: www.brookings.edu/articles/int...
Sherry Glied and I posted a blog noting that cuts to NIH and FDA are grounded in misunderstanding of the basis for grant programs and a failure to consider the health impacts of staff reductions at FDA. See www.brookings.edu/articles/the...
My colleague Yihan Shi and I posted the linked paper showing that all prescription drugs slated for Medicare negotiation and likely to soon be negotiated are making healthy returns on R&D investments. www.brookings.edu/articles/cum...
I posted a paper today with so e facts to highlight
Possible consequences of Medicaid cuts www.brookings.edu/articles/the...
Today Sherry Glied and I posted a commentary on Health Affairs Forefront outlining how the HHS reorganization runs counter to RFK's stated goals for the department and any notion of improved efficiency. See the post at www.healthaffairs.org/content/fore...
Sherry Glied and I have critiqued the recent analysis on the impact of Medicaid work requirements on poverty. It is linked here: : www.healthaffairs.org/content/fore...
Unfortunately, Professors Mulligan and Bai who appear to have led the work get a failing grade on this one.
Today scientific American published my op ed on Medicaid cuts and the opioid epidemic. It can be found at www.scientificamerican.com/article/medi...
The following paper may be of interest to folks following the IRA nam10.safelinks.protection.outlook.com?url=https%3A...